Hansoh Pharmaceutical Group (HKG:3692) obtained clinical trial approval in China for HS-10529, according to a late Tuesday disclosure with the Hong Kong Exchange.
HS-10529 will be investigated as a treatment for advanced solid tumors, including pancreatic cancer, colorectal cancer, and non-small cell lung cancer with KRAS G12D mutations.
The stock slipped over 2% in afternoon trade on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.